Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali's Shareholders of the Previously Announced Business Combination

Core Viewpoint - Semnur Pharmaceuticals, Inc. has received approval from Denali Capital Acquisition Corp's shareholders for a business combination, which is expected to close in September 2025, allowing Semnur to operate as the combined entity [1][2]. Company Overview - Semnur Pharmaceuticals is a majority-owned subsidiary of Scilex Holding Company, focusing on non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][4]. - Scilex Holding Company is dedicated to developing and commercializing therapies that address high unmet medical needs in pain management [4]. Business Combination Details - The business combination was approved during an Extraordinary General Meeting held on September 3, 2025, where all proposals were accepted [2]. - Denali has filed a Current Report on Form 8-K with the SEC to disclose the voting results from the meeting [3]. Product Portfolio - Scilex's commercial products include: - ZTlido, a topical lidocaine product for neuropathic pain [4]. - ELYXYB, an FDA-approved oral solution for acute migraine treatment [4]. - Gloperba, a liquid oral version of colchicine for gout flare prophylaxis [4]. - Scilex has three product candidates in development: - SP-102 (SEMDEXA™), a viscous gel for treating lumbosacral radicular pain, which has completed a Phase 3 study [5]. - SP-103, a next-generation lidocaine topical system for acute pain, recently completing a Phase 2 trial [5]. - SP-104, a low-dose naltrexone for fibromyalgia treatment [5]. Market Position - Semnur is positioned as a late-stage specialty pharmaceutical company focused on novel non-opioid pain therapies, with its lead product candidate being SP-102 [8].